Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Preferred Stock Liabilities (2022 - 2023)

Historic Preferred Stock Liabilities for Serina Therapeutics (SER) over the last 2 years, with Q4 2023 value amounting to $36.4 million.

  • Serina Therapeutics' Preferred Stock Liabilities rose 3630400.0% to $36.4 million in Q4 2023 from the same period last year, while for Dec 2023 it was $36.4 million, marking a year-over-year increase of 3630400.0%. This contributed to the annual value of $36.4 million for FY2023, which is 3630400.0% up from last year.
  • Serina Therapeutics' Preferred Stock Liabilities amounted to $36.4 million in Q4 2023, which was up 3630400.0% from $21.1 million recorded in Q3 2023.
  • Serina Therapeutics' 5-year Preferred Stock Liabilities high stood at $36.4 million for Q4 2023, and its period low was $100000.0 during Q4 2022.